newsfilter
← Latest News
GlobeNewswire·

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

  • Cadrenal Therapeutics Inc. (NASDAQ: CVKD) announced CEO Quang X. Pham will attend the 28th Annual H.C. Wainwright Global Investment Conference from September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.
  • A pre-recorded presentation will be accessible on demand via the H.C. Wainwright conference portal starting September 11, 2026, at 7:00 a.m. ET, with slides available on Cadrenal's investor relations website.
  • Mr. Pham is scheduled to discuss the Cardiac Acute Critical Care Franchise, the structured partnering process for CAD-1005, frunexian, & tecarfarin, & recent Phase 2 clinical data on CAD-1005.
  • One-on-one investor meetings will be available at the conference; interested parties can schedule by contacting H.C. Wainwright at meetings@hcwco.com or Cadrenal's investor relations at CVKD@lythampartners.com.
  • CAD-1005 is a novel investigational therapeutic designed to inhibit 12-lipoxygenase for heparin-induced thrombocytopenia (HIT) & Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), holding FDA Orphan Drug & Fast Track designations for HIT.
  • Tecarfarin is a late-stage oral vitamin K antagonist in development for preventing blood clots in patients with chronic anticoagulation needs, including those with end-stage kidney disease, atrial fibrillation, left ventricular assist devices, & Kawasaki disease.
  • Cadrenal recently requested FDA Rare Pediatric Disease Designation for tecarfarin regarding the prevention of life-threatening blood clots in children with Kawasaki disease, having already received Orphan Drug & Fast Track designations.
  • Second-generation 12-LOX oral therapeutics (CAD-2000) are in development for chronic indications.